HHEX and colorectal carcinoma: With the goal of identifying new easy-to-assay molecular markers for CRC to inform the clinical decision-making and improve patient outcomes, we have here applied untargeted systems glycobiology approaches to biospecimens from CRC patients revealing that noncanonical paucimannosidic proteins and the underpinning biosynthetic glyco-enzyme, HEXB, are molecular signatures that accompany CRC and that the plasma Hex activity is a promising prognostic marker candidate to stratify CRC patient survival.